- Home
- ADIL vs APVO Comparison
ADIL vs APVO Comparison
Compare ADIL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- APVO
- Stock Information
- Founded
- ADIL 2010
- APVO 2016
- Country
- ADIL United States
- APVO United States
- Employees
- ADIL N/A
- APVO N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- APVO Health Care
- Exchange
- ADIL Nasdaq
- APVO Nasdaq
- Market Cap
- ADIL 3.9M
- APVO 4.1M
- IPO Year
- ADIL 2018
- APVO N/A
- Fundamental
- Price
- ADIL $0.34
- APVO $3.23
- Analyst Decision
- ADIL Strong Buy
- APVO Strong Buy
- Analyst Count
- ADIL 1
- APVO 1
- Target Price
- ADIL $8.00
- APVO $5,920.00
- AVG Volume (30 Days)
- ADIL 22.2M
- APVO 6.6M
- Earning Date
- ADIL 08-12-2025
- APVO 08-07-2025
- Dividend Yield
- ADIL N/A
- APVO N/A
- EPS Growth
- ADIL N/A
- APVO N/A
- EPS
- ADIL N/A
- APVO N/A
- Revenue
- ADIL N/A
- APVO N/A
- Revenue This Year
- ADIL N/A
- APVO N/A
- Revenue Next Year
- ADIL N/A
- APVO N/A
- P/E Ratio
- ADIL N/A
- APVO N/A
- Revenue Growth
- ADIL N/A
- APVO N/A
- 52 Week Low
- ADIL $0.22
- APVO $2.81
- 52 Week High
- ADIL $3.00
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- ADIL 50.21
- APVO 34.28
- Support Level
- ADIL $0.22
- APVO $2.81
- Resistance Level
- ADIL $0.27
- APVO $13.11
- Average True Range (ATR)
- ADIL 0.08
- APVO 1.10
- MACD
- ADIL -0.01
- APVO 0.30
- Stochastic Oscillator
- ADIL 53.15
- APVO 4.08
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.